Santa Clara, USA) in the treatment of 101 patients with de novo native coronary artery lesions. The current analysis included 51 patients with 143 OCT pullbacks (Baseline: 52, 6 month: 25, 1 year: 22, 2 year: 26, 3 year: 18) who underwent OCT at baseline and follow-up. The presence of acute disruption or late discontinuities was diagnosed by the presence on OCT of stacked, overhung struts or isolated intraluminal struts disconnected from the expected circularity of the device. Results: Out of 51 patients with OCT imaging post-procedure, acute scaffold disruption was observed in 2 patients (3.9%). One patient had a target lesion revascularization presumably related to the disruption. Out of 49 patients without acute disruption, late discontinuities were observed in 21 patients. There were no major adverse cardiac events associated with this finding except for one patient who had a non-ischemia driven target lesion revascularization. Conclusions: Acute scaffold disruption is a rare iatrogenic phenomenon that has been anecdotally associated with anginal symptoms, whereas late strut discontinuity is observed in approximately 40% of patients and could be viewed as a serendipitous OCT finding of a normal bioresorption process without clinical implications.
Background: During the first 3 years after implantation of an everolimus-eluting poly-l-lactic-acid (PLLA) scaffold (Absorb BVS, Abbott Vascular), the polymeric struts are progressively hydrolyzed and subsequently replaced by proteoglycan. Eventually, the provisional matrix becomes cellularized by smooth muscle cell or connective tissue. Previous preclinical studies demonstrated that Optical Coherence Tomography (OCT) by visual assessment is unable to distinguish polylactide from proteoglycan, and therefore is not sensitive enough to investigate the process of bioresorption. Light intensity assessment of strut on OCT might be a sophisticated method to quantify the phenomenon of cellularization. The aim of this study was to test this novel quantitative method on serial human OCT. Methods: In the ABSORB Cohort B2 trial, 17 patients underwent serial frequencydomain OCT post procedure, at 1year and at 3 years. Corresponding struts in corresponding cross-sections at different times were detected by using anatomical landmarks. The region of interest (ROI) encompassing the corresponding struts was selected visually; two different intensity assessments were performed: one was "Area assessment" for measuring the mean intensity value of the strut area line and the other was "Line assessment" for measuring the peak intensity value along a single scan line. Results: A total of 172 corresponding struts were sequentially analyzed. The results are shown in the table. (Figure) 1 Stanford University, Stanford, CA Background: Different stent material/design and post-dilatation strategies can impact on final stent expansion. The aim of this study was to evaluate the acute recoil of the latest-generation coronary stents compared with conventional stents. Methods: Optical coherence tomography (OCT) imaging was performed on 3 latestgeneration (LG) stents (Multi-Link 8, Integrity and Element), 2 conventional cobalt chromium (CC) stents (Driver and Vision) and 3 conventional stainless steel (SS) stents (Select, Liberté and S-Stent) (F3.0 mm, N¼6 each) during and after balloon inflation in a silicone-tube bench model. After nominal-pressure deployment (15 sec), a single long (30 sec) vs. multiple short (10 sec x 3 times) post-dilatations were performed using a non-compliant balloon (3.25 mm, 20 atm). Results: Stent areas during deployment significantly varied among 3 groups (LG 6.5, CC 7.1, SS 6.1 mm 2 , p<0.01). Recoil after deflation in LG was similar to SS, but smaller than CC (-8.1%, -8.2%, -12.1%, p<0.01). Significant recoil was also observed after post-dilatation, regardless of stent types and inflation strategies. Overall, multiple short inflations achieved greater final stent areas than single long inflation ( Figure) . Final stent area in LG was similar to CC, but smaller than SS (7.5, 7.5, 7.9 mm 2 , p<0.01). In the LG group, these results were not different among 3 stent types.
Conclusions: Real-time OCT revealed significant acute recoil in the latest-generation stents as well as conventional stents. For post-dilatation, multiple short inflations may be better than single long inflation in optimizing the final stent expansion.
TCT-595
Location Background: The aim of this study was to evaluate the impact of stent design and side branch access on final strut apposition during bifurcation stenting. Methods: 42 samples of 6 different commercially available Drug Eluting Stents (DES) were deployed in an identical in-vitro coronary bifurcation model. The platform tested were 16mm to 28mm in length and included the Everolimus eluting Xience V (n¼9, Abbott Vascular, Santa Clara, CA), Promus Element (n¼9, Boston Scientific, Natick, MA), the Paclitaxel eluting Taxus Liberte (n¼8, Boston Scientific, Natick, MA), the Biolimus eluting Biomatrix Flex (n¼7, Biosensors International, Morges, Switzerland), the Sirolimus eluting Cypher Select (n¼4, Cordis, Warren, NJ) and the Zotaroliums eluting Resolute stents (n¼5), Medtronic, Santa Rosa, CA). Kissing Balloon (KB) optimization was performed after either a proximal or a distal recrossing of the guidewire and results were analyzed by Micro Computed-Tomography. Results: When the Side Branch (SB) was accessed through a mid-distal cell, average rates of strut malapposition observed inside the bifurcation confluence area remained low with no significant differences observed between the different platforms tested [15.4%-23.6%]. Conversely, proximal instead of distal cell recrossing toward the side branch produced TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM www.jacctctabstracts2013.com B180 JACC Vol 62/18/Suppl B j October 27-November 1, 2013 j TCT Abstracts/POSTER/Intravascular Imaging and PCI a significant higher rates of malapposed strut, particularly toward the SB ostium (40.6 AE 6.0 % versus 26.0 AE 5.7 %, p¼0.0005), as well as a higher SB lumen residual stenosis than after mid-distal recrossing (39.7 AE 7.1 % versus 18.9 AE 8.0 %, p < 0.0001). In-vivo Optical Coherence Tomography (OCT) analysis on 52 patients undergoing elective treatment of bifurcation lesions using provisional stenting showed that using OCT to guide cell recrossing is feasible and can reduce significantly strut malapposition in bifurcation. Patients who were treated using OCT-guided distal recrossing had a significantly lower number of malapposed stent struts, especially in the quadrants towards the SB ostium than in the angiography-guided group (9.5% vs 42.3%, p<0.0001).
Conclusions: Optimal distal cell recrossing of the guidewire is critical to ensure a successful stent optimization in bifurcation PCI.
TCT-596
Early Vascular Restoration following treatment of single de-novo coronary artery lesions with the DESolve Nx Novolimus Eluting Bioresorbable Coronary Scaffold System (NEBCSS) at 6 months: Insights from the Serial IVUS analysis of the pivotal, prospective, multicentre, DESolve NX Trial Background: The DESolve Bioresorbable Scaffold is a novel drug-eluting device combining a PLLA-based scaffold coated with a bioresorbable polylactide-based polymer and a potent anti-proliferative sirolimus metabolite, Novolimus. The drug dose is 5 mcg per mm of scaffold length. An early benefit with regard to vessel restoration is a potential feature of this unique technology. The aim of this study is to assess the serial changes in the vessel treated with the DESolve scaffold using IVUS technology. Methods: The DESolve NX is a pivotal, prospective and multicentre clinical trial, which enrolled 126 patients with de novo coronary lesions treated with a single scaffold available in three diameters (3.0, 3.25 and 3.5) and two lengths (14 and 18 mm). The first 46 patients enrolled in this trial were part of an IVUS sub-study, which consisted of a paired analysis of the automatic pullbacks performed at the end of the baseline procedure and at six-month follow-up (an additional 24 month follow up will also be performed). All analyses are being performed by an independent IVUS core lab. Results: The mean age of the study population was 62 years, 68% of which were men and 21% had diabetes. Pre procedure reference vessel lesion length and diameter were 11.2 AE 3.8mm and 3.06 AE 0.31, respectively. 40 of the 46 patients enrolled in the IVUS sub study had serial analyses available at 6 months that demonstrated a significant increase in mean lumen (D 9.0%, p ¼ <0.001), scaffold (D 15.7%, p ¼ <0.001) and vessel (D 16.8 %, p ¼ <0.001) areas between baseline and 6 months and low % volume obstruction (5.05%) with no case of late acquired scaffold incomplete apposition or aneurysm formation. Conclusions: The DESolve scaffold is the first scaffold to demonstrate lumen area enlargement with no chronic recoil at 6 month follow up with no evidence of aneurysms. Serial IVUS results at 6 months showed effective neointimal suppression and no late acquired strut malapposition suggesting the natural ability of the scaffolded vessel to remodel at 6 months.
TCT-597
Predictors Background: While a smaller minimum stent cross-sectional area (MSA) predicts adverse events (stent restenosis and thrombosis), predictors of stent underexpansion have not been fully investigated.
Methods: ADAPT-DES was a prospective, multicenter, registry of 8,583 consecutive pts with undergoing PCI with DES. Among 2064 pts enrolled in a pre-specified intravascular ultrasound (IVUS) substudy, 769 pts with 889 lesions were examined by both pre and post-PCI IVUS. Stent expansion (ST-Exp) was calculated as MSA divided by average of proximal and distal stent edge lumen area; %ST-Exp was divided into (1) !70% (adequate expansion), (2) 60-70% (moderate underexpansion), and (3) <60% (severe underexpansion). Results: Lesion length was longer and maximum arc of superficial calcium was greater in the severe underexpansion group than in the other 2 groups (Table) . These findings were independent of vessel size and were also similar when stent expansion was divided into tertiles: highest tertile of stent expansion (ST-exp >83%), middle tertile (73%-83%), and lowest tertiles (ST-exp <73%). Multiple logistic regression analysis revealed that lesion length [OR 1.80 per 10 mm (1.54, 2.09), p<0.0001] and maximum arc of superficial calcium [OR 1.13 per 90 (1.30, 2.00), p¼0.006] were independently associated with severe stent underexpansion (ST-Exp<60%). ROC curve analysis showed that cut-off values of lesion length and maximum arc of superficial calcium that best predicted stent expansion <60% (severe underexpansion) were 42.0 mm and 127 . Conversely, plaque burden was unrelated to stent expansion. Conclusions: Lesion length and the extent of superficial calcium are the strongest determinants of stent underexpansion.
TCT-598
Mechanisms In patients with late acquired ISA, the mechanism was positive remodeling in 73.7% of the stented lesions (post-intervention EEM CSA 21.0 mm2 (IQR 13.5 to 26.9 mm2) vs. follow-up EEM CSA 27.4 mm2 (IQR 18.6 to 31.3 mm2), p¼0.001, and maximum ISA CSA was 3.5 mm2 (IQR 1.3 to 5.8 mm2). In 26.3% of the patients with late acquired ISA, negative remodeling and plaque/thrombus resolution was seen. Conclusions: In STEMI patients "acute" ISA resolved in one third of the stented lesions, mainly due to plaque progression. "Late acquired" ISA was predominantly due to positive remodeling. www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
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